Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 26 February 2013 | By Alexander Gaffney, RAC
A new final regulation just released by the US Food and Drug Administration (FDA) amends an existing regulation to include minor additional safeguards for pediatric patients, including children, enrolled in clinical trials.
The long-anticipated rule has been in the works since 2001, when FDA released an interim rule meant to comply with the Children's Health Act of 2000, which mandates that all pediatric research in the US offer subject additional protections to ensure their safety.
These protections include requirements that institutional review boards review pediatric research and ensure that the research meets seven criteria:
Importantly, the rule also calls on all companies to conduct a pediatric assessment for new products, including active ingredients, indications, dosing regimens and dosage forms, unless those requirements were explicitly waived or deferred by FDA.
Sponsors who complete the difficult pediatric trials are eligible for additional incentives, including six months of marketing exclusivity also known as pediatric exclusivity, which applies to all other forms of marketing exclusivity and not just the pediatric application. Those incentives were made permanent in 2012 under the FDA Safety and Innovation Act (FDASIA).
FDA said it has made four significant changes to the final rule relative to its interim rule:
The final rules come into effect 30 days after its publication in the Federal Register, scheduled for 26 February 2013. A similar rule was passed by FDA on 19 February 2013 pertaining to medical device submissions and pediatric data requirements.
Tags: Protections, Pediatric, clinical trials